Sector News

Fujifilm plots $1.6B expansion at CDMO sites in Denmark and Texas, adding 450 jobs

July 3, 2022
Life sciences

Fujifilm isn’t slowing down on its expansion roll. Just a few months after it bought Shenandoah Biotechnology for an undisclosed sum, the Japanese conglomerate has unveiled a $1.6 billion investment to expand the cell culture manufacturing services of Fujifilm Diosynth Biotechnologies, a CDMO subsidiary.

The investment will benefit its sites in Hillerød, Denmark, and Texas, and create approximately 450 jobs.

In Denmark, Fujifilm Diosynth will expand its capacity to support large-scale batch production through the addition of eight 20,000-liter bioreactors and two downstream processing streams, making it largest end-to-end CDMO in Europe. Once the expansion is complete, the site will feature twenty 20,000-liter bioreactions for drug substance production, plus drug product and finished good services.

The Denmark facility’s sustainable features, such as an electric boiler rather than one powered by natural gas, will support Fujifilm’s new Green Value Climate Strategy and remove its dependency on fossil fuels. Fujifilm Diosynth is also investing in programs that aim to reduce water consumption.

At the Texas site, the company’s investment will expand its cell culture manufacturing capabilities and enable continuous processing.

The expansion will help Fujifilm fulfill “rapidly growing demand for high volume production” of biopharmaceuticals, Teiichi Goto, president and CEO of Fujifilm, said in a statement. The major investment will enable the company to be “the best partner for customers as the premier bio CDMO,” Goto added.

The move comes amid something of an expansion spree for the company. In January, the Fujifilm acquired a cell therapy plant from Atara Biotherapeutics for $100 million in Thousand Oaks, California, agreeing to a long-term deal to help produce treatments in Atara’s clinical pipeline.

Last January, the company spent $76 million to build on a new 40,000-square-foot facility in Watertown, Massachusetts. The move was part of a push to deliver $1.8 billion in CDMO revenues by 2024.

But the company’s biggest move came just days before the Watertown lease, when it pledged $2 billion for a large cell culture site in the U.S., which will be operational by the spring of 2025.

By Zoey Becker


comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.